- Home
- BTAI vs IMCC Comparison
BTAI vs IMCC Comparison
Compare BTAI & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- IMCC
- Stock Information
- Founded
- BTAI 2017
- IMCC 1980
- Country
- BTAI United States
- IMCC Israel
- Employees
- BTAI N/A
- IMCC N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- IMCC Medicinal Chemicals and Botanical Products
- Sector
- BTAI Health Care
- IMCC Health Care
- Exchange
- BTAI Nasdaq
- IMCC Nasdaq
- Market Cap
- BTAI 6.6M
- IMCC 7.5M
- IPO Year
- BTAI 2018
- IMCC N/A
- Fundamental
- Price
- BTAI $2.13
- IMCC $2.16
- Analyst Decision
- BTAI Buy
- IMCC
- Analyst Count
- BTAI 4
- IMCC 0
- Target Price
- BTAI $37.00
- IMCC N/A
- AVG Volume (30 Days)
- BTAI 279.4K
- IMCC 11.3K
- Earning Date
- BTAI 03-11-2025
- IMCC 03-27-2025
- Dividend Yield
- BTAI N/A
- IMCC N/A
- EPS Growth
- BTAI N/A
- IMCC N/A
- EPS
- BTAI N/A
- IMCC N/A
- Revenue
- BTAI $2,276,000.00
- IMCC $38,042,859.00
- Revenue This Year
- BTAI $105.36
- IMCC $22.59
- Revenue Next Year
- BTAI $46.93
- IMCC $32.86
- P/E Ratio
- BTAI N/A
- IMCC N/A
- Revenue Growth
- BTAI 83.25
- IMCC N/A
- 52 Week Low
- BTAI $2.10
- IMCC $1.61
- 52 Week High
- BTAI $56.00
- IMCC $8.10
- Technical
- Relative Strength Index (RSI)
- BTAI 28.68
- IMCC 44.61
- Support Level
- BTAI $2.18
- IMCC $2.11
- Resistance Level
- BTAI $2.60
- IMCC $2.33
- Average True Range (ATR)
- BTAI 0.44
- IMCC 0.16
- MACD
- BTAI -0.08
- IMCC 0.00
- Stochastic Oscillator
- BTAI 0.94
- IMCC 20.00
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.